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E-mail address: lym@knu.ac.kr (Y.M. Lee).We have reported that vascular endothelial growth factor (VEGF)-A induces the proliferation of
human pulmonary valve endothelial cells (HPVECs) through nuclear factor in activated T cells
(NFAT)c1 activation [1]. Here we show that VEGF-A increases the migration of HPVECs through
NFATc1 activation, suggesting that VEGF-A/NFATc1 regulates the migration of HPVECs. To learn
how this pathway may be involved in post-natal valvular repair, HPVECs were treated with VEGF-
A, with or without cyclosporine A to selectively block VEGF–NFATc1 signaling. Down Syndrome crit-
ical region 1 (DSCR1) and heparin-binding EGF-like growth factor (HB-EGF) are two genes identiﬁed
by DNA microarray as being up-regulated by VEGF-A in a cyclosporine-A-sensitive manner. DSCR1
silencing increased the migration of ovine valve endothelial cells, whereas HB-EGF silencing inhib-
ited migration. This differential effect suggests that VEGF-A/NFATc1 signaling might be a crucial
coordinator of endothelial cell migration in post-natal valves.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Developmental heart malformations are the most frequently
identiﬁed congenital anomaly in children [2]. Among these, heart
valve defects often require the defective valve to be replaced in a
surgical procedure. Thereafter, the integrity and function of the
valve must be followed carefully. However, little is known about
the genes that regulate the integrity and maintenance of valve
function throughout the post-natal period and adulthood.
The nuclear factor of activated T cells (NFAT) family of tran-
scription factors was ﬁrst identiﬁed in immune cells [3]. There
are four isoforms of this protein, NFATc1, c2, c3, and c4 (alternative
names are NFAT1–4). While knockout of other NFAT proteins pro-chemical Societies. Published by E
cells; VEGF, vascular endo-
or; EMT, endothelial–mesen-
e critical region 1; HB-EGF,
an pulmonary valve endothe-
ikkopf 1; IGFBP, insulin-like
ain receptor; ED, embryonicduces defects in the immune system or other organs [4,5], knock-
out of NFATc1 blocks the formation of the pulmonary and aortic
valves, causing embryonic lethality at embryonic day (ED) 14–15
[6,7]. Cyclosporin A (CsA) is an inhibitor of calcineurin, a phospha-
tase that activates NFATs and allows their translocation into the
nucleus where they then regulate transcription. Thus, CsA inhibits
calcineurin–NFAT signaling pathways [5]. Vascular endothelial
growth factor-A (VEGF-A), a central regulator of angiogenesis and
vasculogenesis, activates NFATc1 in human valve endothelial cells
isolated from normally discarded surgical specimens [1]. We and
others showed previously that VEGF-A rapidly activates NFATc1
translocation into the nucleus and that this is required for the full
mitogenic activity of VEGF-A in human pulmonary valve endothe-
lial cells (HPVECs) [1,8].
The primordial heart valve cushions are deﬁned by swellings
in the atrioventricular (AV) junction and outﬂow tract at ED 9.5
in mice. The cushion is initially made up of extracellular matrix
components, but as endocardial endothelial cells are stimulated
to undergo endothelial–mesenchymal transdifferentiation
(EMT), the cellularity of the cushion increases due to the migra-
tion of endothelial cells [9]. The signals from myocardium that
induce EMT of the endothelium are not well deﬁned, but onelsevier B.V. All rights reserved.
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2) [10–13]. In clonal endothelial cells isolated from sheep heart
valves, transforming growth factor (TGF)-b induces EMT signiﬁ-
cantly [14].
In zebraﬁsh, the jekyll mutant has a disruption in the gene
encoding uridine 50-diphosphate glucose dehydrogenase, which is
essential for the synthesis of hyaluronic acid, an abundant compo-
nent of the extracellular matrix in endocardial cushions [15]. The
jekyll mutant zebraﬁsh embryo exhibits regurgitation or toggling
of blood between the atrium and ventricle as well as defects in cell
differentiation at the AV boundary, indicating a defect in valve for-
mation. Using a chemical approach, we tested the effect of adding a
VEGF receptor-selective inhibitor to wild-type zebraﬁsh embryos.
Blocking VEGF-A signaling for 4 h induced a phenotype remarkably
similar to that of the jekyllmutant [16]. This ﬁnding suggested that
VEGF-A is a signiﬁcant up-stream regulator of NFATc1 and impli-
cated VEGF-A and VEGFR-2 in valvulogenesis. However, the
down-stream targets of VEGF–NFATc1 signaling have not yet been
identiﬁed in valve endothelial cells.
In this study, we investigated the genes that are up- and down-
regulated by VEGF–NFATc1 to further understand the function of
VEGF–NFATc1 signaling in valve endothelial cells. Among up-regu-
lated genes, Down Syndrome critical region 1 (DSCR1) and hepa-
rin-binding EGF-like growth factor (HB-EGF) showed opposing
inﬂuences on the migration of HPVECs. Since increased migration
is a key cellular event in EMT, these results suggest that NFATc1
activation by VEGF-A might affect speciﬁc cellular functions that
are regulated during valvulogenesis.2. Materials and methods
2.1. Cell culture
HPVEC and sheep aortic ovine valve endothelial cell (OVEC)
were isolated from human pulmonary valve leaﬂets as described
[1,14]. The passages of HPVECs and OVECs used in this study were
6–9 and 9–13, respectively.
2.2. Immunoﬂuorescence assay
HPVECs were ﬁxed in 4% paraformaldehyde, permeabilized
with 0.5% Triton X-100, and incubated with mouse anti-human
NFATc1 monoclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) followed by FITC-conjugated anti-mouse IgG.
2.3. Western blot analysis
Equal amounts of protein extracts in a SDS-lysis buffer were
subjected to 10% SDS–PAGE analysis and transferred to a nitro-
cellulose membrane. The anti-NFATc1 antibody used was ob-
tained from Santa Cruz Biotechnology. An enhanced
chemiluminescence system (Pierce, Woburn, MA) was used for
detection.Fig. 1. VEGF stimulates the translocation of NFATc1 into the nucleus and CsA
inhibits this activation. (A) HPVECs were stimulated with 50 ng/ml VEGF for 30 min
(b) or for 3 h (c) or with CsA (1 lM) plus VEGF for 30 min (d). Cells were incubated
with a mouse control IgG (a) or with mouse anti-human NFATc1 (b–d), followed by
anti-mouse conjugated FITC. In panel d, HPVECs were preincubated with 1 lM CsA
for 2 h prior to addition of VEGF. Photographs were taken at 630magniﬁcation. (B)
The expression of NFATc1 was evaluated in cell lysates from HPVEC in EBM-2 with
growth factors (lane 1) and EBM-2 without growth factor (lanes 2–8) by Western
blot. Cells were treated with VEGF (50 ng/ml) in the absence (lanes 2, 4, and 6) or
presence (lanes 3, 5, 7, and 8) of 1 lM CsA for 5 h (lanes 2 and 3), 10 h (lanes 4 and
5), 20 h (lanes 6 and 7), and 48 h (lane 8). Alpha-tubulin levels are shown as loading
control.2.4. Total RNA isolation and DNA microarray analysis
HPVEC cells were treated with VEGF (50 ng/ml) and with or
without CsA (1 lg/ml) for 3 h. Total RNA was isolated from the
treated cells by single-step procedure with Trizol reagent (Invit-
rogen, Gaithersburg, MD). The quality of total RNA (260/280 nm
ratio) was excellent (above 2.0) and used for further cRNA syn-
thesis and chip hybridization procedure with Gene Chip
(HU133A, Affymetrix Inc., Santa Clara, CA). All microarray data
were analyzed at the NetAffx Analysis Center on Affymetrix
web site (http://www.affymetrix.com/analysis/index.affx).2.5. Knock-down of DSCR1 and HB-EGF with siRNA
OVEC cells were transfected with double stranded RNA using a
MicroPorator (NanoEnTek, Seoul, Korea). After transfection, cells
were harvested for the detection of gene expression by semi-
quantitative RT-PCR. The scrambled control siRNA sequence was
50-CUGAUGACCUGAGUGAAUGdTdT-30, the DSCR1 sequence was
50-CUGAUUGCCUGUGUGGCAA dTdT-30, and the HB-EGF sequence
was 50-UGCCGUCGGUGGUGCUGAUGAAdTdT-30 (Bioneer, Daejeon,
Korea).
2.6. Cell migration assay
The bottom of transwell ﬁlters (8 lmporosity polycarbonate ﬁl-
ters, Costar, USA) was coated with 0.5 mg/ml type I collagen. The
lower chamber of each well contained a low serum media with
or without VEGF. In the upper chamber of the transwell plate,
5  104 cells were resuspended in 1 ll EMB and plated. After
24 h, cells were ﬁxed with methanol and stained with hematoxylin
and eosin (Sigma, St. Louis, MO). The cells on the upper surface of
the ﬁlter were removed and the cells that had migrated to the low-
er chamber were counted using a light microscope with a 200
magniﬁcation objective. Each sample was assayed in triplicate,
and repeated twice.
2.7. Statistical analysis
ANOVA tests were performed to assess the signiﬁcance of differ-
ences between control and experimental groups. The level of sig-
niﬁcance was set at P < 0.01 or P < 0.05. Results are presented as
the means ± S.D. (standard deviation).
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3.1. VEGF stimulates the nuclear translocation of NFATc1 and CsA
blocks NFATc1 activation
We previously studied the function of NFATc1 in valvular endo-
thelium using HPVECs isolated from human pulmonary valve leaf-
lets [1]. VEGF treatment (50 ng/ml) rapidly induced NFATc1
translocation into the nucleus within 30 min (Fig. 1A-b); this trans-
location was sustained for 3–5 h (Fig. 1A-c and data not shown).
CsA completely blocked the VEGF-induced NFATc1 translocation
(Fig. 1A-d). Long-term exposure to VEGF for 3 h sustained NFATc1
activation (Fig. 1A-c). To conﬁrm the activation of NFATc1 we per-
formed a Western blot analysis and found that dephosphorylation
of NFATc1 was induced by VEGF after 5 h and that treatment with
CsA blocked the dephosphorylation of NFATc1, which could be
seen as the lower mobility of the phosphorylated form on an
SDS–PAGE gel (Fig. 1B). However, the sustained treatment of VEGF
(10 or 20 h) decreased NFATc1 protein level but showed the
NFATc1 activation might occur independently of its protein level
at these time points (Fig. 1B). Thus, we collected total RNA from
HPVECs after VEGF treatment for 3 h, with or without CsA, to iden-
tify the genes regulated by NFATc1 activation.
3.2. Genes regulated by VEGF stimulation
To identify genes regulated by VEGF–calcineurin pathway
including NFATc1, and not by other VEGF-stimulated pathways,Table 1
Genes regulated in VEGF stimulation in HPVEC categorized by biological functions.
Gene title
Cell growth, size, differentiation regulation
Insulin-like growth factor binding protein 7
Cysteine-rich, angiogenic inducer, 61
SHC (Src homology 2 domain containing) transforming protein 1
Quiescin Q6
Neuroepithelial cell transforming gene 1
Deleted in liver cancer 1
Tumor protein p53 (Li-Fraumeni syndrome)
Insulin-like growth factor binding protein 3
Heart development
PDZ and LIM domain 5
DSCR-1 (Down Syndrome critical region 1)
Muscle development
Muscle blind-like (Drosophila)
CUG triplet repeat, RNA binding protein 2
Heparin-binding EGF-like growth factor (HB-EGF)
MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2
Filamin B, beta (actin binding protein 278)
Jagged-1 (Alagille syndrome)
MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2
Tropomyosin 4
Utrophin (homologous to dystrophin)
Regulation of Wnt receptor signaling pathway
Dickkopf homolog 1 (Xenopus laevis) (DKK1)
Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box)
Viral infectious cycle
CD81 antigen (target of anti-proliferative antibody 1)
Interleukin 8 (IL-8)
C-terminal binding protein 1
Chemokine (C-C motif) ligand 2 (CCL2)
Upstream binding protein 1 (LBP-1a)
Chromosome 1 open reading frame 139
Gene title
Regulation of vascular permeability
Angiomotin
Tube development or cardiac cell differentiation
Bone morphogenetic protein 10 (BMP10)we compared gene expression levels (microarray results) from
cells treated with VEGF to those from cells treated with VEGF plus
CsA. VEGF–NFATc1 regulated genes would be increased or de-
creased by VEGF but not affected by VEGF plus CsA. Although
CsA is an inhibitor of all calcineurin phosphatase activity, CsA
treatment concurrent with VEGF treatment should block only
NFATc1, because VEGF does not activate NFATc2, c3, or c4 in
HPVECs [1]. However, we cannot exclude the possibility that some
of our results are due to non-speciﬁc blocking of calcineurin
pathways that do not involve NFATc1 [4]. We categorized the sig-
niﬁcantly up-regulated genes by biological functions: cell growth-
and differentiation-related, heart development-related, muscle
development-related, Wnt signaling-related genes and viral infec-
tion-related genes (Table 1). A number of genes with roles in car-
diac development were identiﬁed. For example, cystein-rich
angiogenic inducer 61 (CYR61) regulates cell adhesion, migration,
and proliferation through binding to integrin receptors and hepa-
ran sulfate proteoglycans. CYR61 deﬁcient mice show severe atrio-
ventricular septal defects (AVSD) accompanying endocardial
cushion defects [17]. Another identiﬁed gene, HB-EGF, is known
to function in cardiac valve morphogenesis, especially in regulating
valve remodeling [18]. HB-EGF null mutant mice demonstrate en-
larged semilunar and atrioventricular heart valves, indicating the
role of this gene in the inhibition of mesenchymal cell proliferation
[18,19]. Dikkopf 1 (DKK1) is a secreted inhibitor of Wnt signaling
that, when overexpressed, has an inhibitory effect on cardiac cush-
ion formation in zebraﬁsh [20]. Mutations in jagged-1, as in human
Alagille syndrome, cause pulmonary valve stenosis [21]. AmongAccession no. Fold increased
201162_at 4.6
201289_at 4.3
201469_s_at 4.3
201482_at 4.9
201829_at 4.3
210762_s_at 4.9
211300_s_at 4.6
212143_s_at 4.3
211681_s_at 4.6
208370_s_at 3.0
201151_s_at 4.9
202158_s_at 4.6
203821_at 4.6
A) 208328_s_at 4.3
208613_s_at 4.6
209098_s_at 4.3
C) 209199_s_at 4.6
212481_s_at 4.3
213022_s_at 4
204602_at 4
212761_at 5.3
200675_at 4.6
202859_x_at 4.6
212863_x_at 4.9
216598_s_at 4.6
218082_s_at 4.6
221958_s_at 4.3
Accession no. Fold decreased
209521_s_at 13
208292_at 16
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ing protein 1, and chemokine ligand 2 have been suggested to af-
fect cardiac function based on the phenotypes of their knockouts
and their expression patterns in cardiac patients [22–24]. How-
ever, many of the other up-regulated genes listed in Table 1 do
not fully deﬁned roles in cardiac development. Insulin-like growth
factor binding protein (IGFBP)-2 was recently identiﬁed as an
angiogenic or cardiogenic molecule in zebraﬁsh [25]. IGFBPs bind
to IGFs and might differentially regulate biological functions in a
tissue-speciﬁc manner. IGFBP-3 expression is increased by serum
deprivation and has an anti-proliferative effect in porcine endothe-
lial cells [26].
The genes that we identiﬁed as signiﬁcantly down-regulated by
VEGF–NFATc1 activation in HPVECs were highly relevant to vascu-
lar permeability and cardiac cell differentiation. Angiomotin, a
receptor for the angiogenesis inhibitor, angiostatin, decreases
VEGF-induced cell migration in vascular endothelial cells, espe-
cially at the polarization of endothelial branching [27]. Therefore,
we can speculate that the VEGF-stimulated endocardial cell migra-
tion might be caused by the inhibition of angiomotin. BMP10 is
highly expressed in Notch1 mutant embryos and was shown to in-
crease myocardial proliferation during cardiac chamber formation
[28]. However, further investigation of the role of BMP10 in endo-
cardial cells of the cardiac valve is needed.Fig. 2. VEGF induces migration of valve endothelial cells in a calcineurin- and KDR-
dependent manner. (A) Cell migration assay with HPVECs using a Boyden chamber
with polycarbonate membrane (8 lM pore size) was performed after VEGF were
treated in a lower chamber and cell seeded onto upper chamber with or without
CsA (0.2 or 0.5 lM) for 24 h. Unmigrated cells were removed and the number of
migrated cells was counted after staining with hematoxylin and eosin (HE).
Signiﬁcant differences from untreated control cells were noted as *P < 0.01. (B) Cells
were treated with bFGF (10 ng/ml), KDR-selective variant VEGF (50 ng/ml), or VEGF
(50 ng/ml) and a migration assay was performed as described in (A). Signiﬁcant
differences from untreated control cells were noted as *P < 0.01. Data represent
means ± S.D. of two different experiments. Each assay was performed in triplicate.3.3. VEGF-A increases migration of HPVECs in a calcineurin- and
kinase insert domain receptor (KDR)-dependent manner
To identify whether the VEGF–NFATc1 signaling pathway func-
tions in speciﬁc cellular events that occur during EMT, we chose to
perform a migration assay because increased migratory ability is
feature of EMT [9,29]. VEGF-treated HPVECs showed increased
migration (1.4-fold, P < 0.01), but co-treatment with 0.5 lM CsA
decreased cell migration to the control level (Fig. 2A, P < 0.01). This
result suggests that calcineurin-dependent NFATc1 activation con-
tributes to EMT by increasing the migration of valve endothelial
cells. When cells were treated with KDR receptor-selective variant
VEGF [30], cell migration was almost equivalent to that of those
treated with VEGF, suggesting that the effect of VEGF on HPVEC
migration is mediated by VEGFR-2. In contrast, bFGF had no effect
HPVEC migration (Fig. 2B).
3.4. DSCR1 and HB-EGF induced by VEGF demonstrate opposing effects
on the migration of valve endothelial cells
To further analyze the effect of VEGF on valve EMT, we selected
two different genes among those up-regulated by VEGF compared
to VEGF plus CsA. DSCR1 is a direct transcriptional target ofFig. 3. DSCR1 and HB-EGF induced by VEGF have opposite effects on cardiac valve
endothelial cell migration. (A) HPVECs were treated with VEGF (50 ng/ml) and/or
CsA (1 lM) for 1, 3, or 6 h and total RNA was collected for RT-PCR analysis. Beta-
actin was used as an internal control. (B) OVECs were transfected with siRNA
targeting DSCR1 or HB-EGF. A reduced mRNA level (a) was conﬁrmed by RT-PCR.
Beta-actin was used as an internal control. A migration assay was performed with
DSCR1 and HB-EGF knockdown cells for 24 h in transwell plates (8 lM pore size) in
the presence or absence of VEGF (50 ng/ml). Unmigrated cells were removed;
migrated cells were stained with HE and counted (b). Photomicrographs of
migrated cells were taken for control siRNA (c), DSCR1 siRNA (d), or HB-EGF siRNA
(e) transfectants (200magniﬁcation). Data represent means ± S.D. of two different
experiments and each performed in triplicate. Signiﬁcant differences from control
siRNA transfected cells were noted as *P < 0.01, or from DSCR1 siRNA transfected
cells and control siRNA transfected cells as **P < 0.01.
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EGF knockout mice have thickened valves while NFATc1 knockout
mice exhibit an absence of semilunar or atrioventricular valves
[18,19,5]. However, HB-EGF was up-regulated by VEGF in our
DNA microarray data. Thus we selected these two genes, DSCR1
and HB-EGF for further analysis.
To conﬁrm the DNA microarray data for DSCR1 and HB-EGF, we
performed semi-quantitative RT-PCR after cells were treated with
VEGF in the presence or absence of CsA for 1, 3, or 6 h. The expres-
sion of DSCR1 and HB-EGF was signiﬁcantly up-regulated by VEGF
treatment alone versus co-treatment with VEGF and CsA until 6 h
(Fig. 3A). This conﬁrms the results obtained from the DNA micro-
array, indicating that DSCR1 and HB-EGF are regulated by VEGF–
NFATc1 activation. Next, we performed migration assays with
ovine cells in which either gene had been after knocked-down indi-
vidually. The siRNA silencing of DSCR1 and HB-EGF worked well, as
conﬁrmed by semi-quantitative RT-PCR (Fig. 3B-a). Interestingly,
knock-down of DSCR1 signiﬁcantly increased migration of OVECs
(Fig. 3B-b and -d) compared to scrambled siRNA control, indicating
that DSCR1 might function to inhibit valve EMT. However, knock-
down of HB-EGF signiﬁcantly decreased migration of OVECs
(Fig. 3B-b and -e). This suggests that HB-EGF plays a positive role
in the migratory capability of valve endothelial cells. Even though
we did not treat cells with CsA in both case, we can expect that the
treatment with CsA would not solely potentiate the results in both
silenced cells because the treatment of CsA would inhibit a number
of genes that might play different roles in the migration as these
two genes did.
Ithasbeensuggested thatDSCR1 functionsasanegative feedback
inhibitor for NFATc1 by inhibiting calcineurin [31]. It is thus impor-
tant todeﬁne theprecise cellular behaviors that are regulatedby this
feed-back inhibition. For example, VEGF-inducedNFATc1 activation
enhances the proliferation of HPVECs, suggesting that DSCR1 does
not have a major effect on proliferation [7]. DSCR1 over-expression
in OVECs does not inhibit EMT [32]. Here, our data suggest that
DSCR1 inhibits valve ECmigration. Therefore, it is possible thatVEGF
may inhibit or attenuate EMT through VEGF-induced DSCR1, which
would in turn inhibit cellular migration [31,33,34]. Alternatively,
VEGFmight inhibit TGF-b-inducedEMT through the activity of other
genes. HB-EGF is suggested to stimulate valvulogenesis in some
steps of cardiac development through the BMP signaling pathway
[12,13]. Interestingly, increased activation of BMP signaling mole-
cules such as Smad1, 5, and 8 was observed in hyperplastic valves
of HB-EGF mutants [18], suggesting that HB-EGF may oppose BMP
signaling. A positive function for VEGF in active cellular migration
and EMT (our results, [35]) might be mediated by HB-EGF. HB-EGF,
therefore, appears to act as a negative regulator ofmesenchymal cell
proliferation but a positive regulator of valve endothelial cell migra-
tion during valve development and remodeling. Taken together,
these results suggest that the VEGF–NFATc1 signaling pathway play
a role in EMThomeostasis,whichmay involve themigrationof valve
endothelial cells.
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